Top

Published in:

Open Access 01-05-2018 | Current Opinion

Inappropriate Use of Antimicrobials for Lower Respiratory Tract Infections in Elderly Patients: Patient- and Community-Related Implications and Possible Interventions

Authors: Inger van Heijl, Valentijn A. Schweitzer, Lufang Zhang, Paul D. van der Linden, Cornelis H. van Werkhoven, Douwe F. Postma

Published in: Drugs & Aging | Issue 5/2018

Abstract

The elderly are more susceptible to infections, which is reflected in the incidence and mortality of lower respiratory tract infections (LRTIs) increasing with age. Several aspects of antimicrobial use for LRTIs in elderly patients should be considered to determine appropriateness. We discuss possible differences in microbial etiology between elderly and younger adults, definitions of inappropriate antimicrobial use for LRTIs currently found in the literature, along with their results, and the possible negative impact of antimicrobial therapy at both an individual and community level. Finally, we propose that both antimicrobial stewardship interventions and novel rapid diagnostic techniques may optimize antimicrobial use in elderly patients with LRTIs.

United Nations, Department of Economic and Social Affairs, Population Division. World Population Ageing 2015. 2015 (ST/ESA/SER.A/390).

World Bank Group. Development Knowledge: Data on population ages 65 and above. 2016. https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS. Accessed 29 Nov 2017.

Meyer K. The role of immunity and inflammation in lung senescence and susceptibility to infection in the elderly. Semin Respir Crit Care Med. 2010. https://doi.org/10.1055/s-0030-1265897.CrossRefPubMed

Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis. 2000. https://doi.org/10.1086/313792.CrossRefPubMed

Millett ERC, Quint J, Smeeth L, Daniel R, Thomas S. Incidence of community-acquired lower respiratory tract infections and pneumonia among older adults in the United Kingdom: a population-based study. PLoS One. 2013. https://doi.org/10.1371/journal.pone.0075131.CrossRefPubMedPubMedCentral

Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012. https://doi.org/10.1136/thx.2009.129502.CrossRefPubMed

Janssens J, Krause K. Pneumonia in the very old. Lancet Infect Dis. 2004. https://doi.org/10.1016/S1473-3099(04)00931-4.PubMedCrossRef

Pawelec G. Hallmarks of human “immunosenescence”: adaptation or dysregulation? Immun Ageing. 2012. https://doi.org/10.1186/1742-4933-9-15.CrossRefPubMedPubMedCentral

Sera L, McPherson M. Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy. Clin Geriatr Med. 2012. https://doi.org/10.1016/j.cger.2012.01.007.PubMedCrossRef

10.

Fernández Sabé N, Carratalà J, Rosón B, Dorca J, Verdaguer R, Manresa F, Gudiol F. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore). 2003. https://doi.org/10.1097/01.md.0000076005.64510.87.PubMedCrossRef

11.

van Vught LA, Endeman H, Meijvis SC, Zwinderman AH, Scicluna BP, Biesma DH, van der Poll T. The effect of age on the systemic inflammatory response in patients with community-acquired pneumonia. Clin Microbiol Infect. 2014. https://doi.org/10.1111/1469-0691.12717.PubMedCrossRef

12.

Kothe H, Bauer T, Marre R, Suttorp N, Welte T, Dalhoff K. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J. 2008. https://doi.org/10.1183/09031936.00092507.PubMedCrossRef

13.

Sahuquillo Arce J, Menéndez R, Méndez R, Amara Elori I, Zalacain R, Capelastegui A, Aspa J, Borderías L, Martín Villasclaras J, Bello S, Alfageme I, de Castro F, Rello J, Molinos L, Ruiz Manzano J, Torres A. Age-related risk factors for bacterial aetiology in community-acquired pneumonia. Respirology. 2016. https://doi.org/10.1111/resp.12851.PubMedCrossRef

14.

Capelastegui A, España P, Bilbao A, Gamazo J, Medel F, Salgado J, Gorostiaga I, de Goicoechea L, Jose M, Gorordo I, Esteban C, Altube L, Quintana J. Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC Infect Dis. 2012. https://doi.org/10.1186/1471-2334-12-134.

15.

Gutiérrez F, Masiá M, Rodríguez JC, Mirete C, Soldán B, Padilla S, Hernández I, De Ory F, Royo G, Hidalgo AM. Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. Clin Microbiol Infect. 2005. https://doi.org/10.1111/j.1469-0691.2005.01226.x.CrossRefPubMed

16.

Klapdor B, Ewig S, Pletz M, Rohde G, Schütte H, Schaberg T, Welte T. Community-acquired pneumonia in younger patients is an entity on its own. Eur Respir J. 2012. https://doi.org/10.1183/09031936.00110911.PubMedCrossRef

17.

Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001. https://doi.org/10.1056/NEJM200103013440908.PubMedCrossRef

18.

Reza Shariatzadeh M, Huang J, Marrie T. Differences in the features of aspiration pneumonia according to site of acquisition: community or continuing care facility. J Am Geriatr Soc. 2006. https://doi.org/10.1111/j.1532-5415.2005.00608.x.PubMedCrossRef

19.

Moons KGM, Royston P, Vergouwe Y, Grobbee D, Altman D. Prognosis and prognostic research: what, why, and how? BMJ. 2009. https://doi.org/10.1136/bmj.b375.PubMedCentralCrossRefPubMed

20.

Jain S, Self W, Wunderink R, Fakhran S, Balk R, Bramley A, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015. https://doi.org/10.1056/NEJMoa1500245.CrossRefPubMedPubMedCentral

21.

Huijskens EGW, Koopmans M, Palmen FMH, van Erkel, Adriana JM, Mulder PGH, Rossen JWA. The value of signs and symptoms in differentiating between bacterial, viral and mixed aetiology in patients with community-acquired pneumonia. J Med Microbiol. 2014. https://doi.org/10.1099/jmm.0.067108-0.

22.

Chalmers J, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis. 2014. https://doi.org/10.1093/cid/cit734.CrossRefPubMed

23.

José R, Periselneris J, Brown J. Community-acquired pneumonia. Curr Opin Pulm Med. 2015. https://doi.org/10.1097/MCP.0000000000000150.PubMedCrossRef

24.

Montravers P, Harpan A, Guivarch E. Current and future considerations for the treatment of hospital-acquired pneumonia. Adv Ther. 2016. https://doi.org/10.1007/s12325-016-0293-x.PubMedPubMedCentralCrossRef

25.

Lopez A, Amaro R, Polverino E. Does health care associated pneumonia really exist? Eur J Intern Med. 2012. https://doi.org/10.1016/j.ejim.2012.05.006.PubMedCrossRef

26.

Ewig S, Klapdor B, Pletz M, Rohde G, Schütte H, Schaberg T, Bauer T, Welte T. Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study. Thorax. 2012. https://doi.org/10.1136/thoraxjnl-2011-200630.PubMedCrossRef

27.

Lim WS, Macfarlane JT. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. Eur Respir J. 2001;18(2):362–8.CrossRefPubMed

28.

Polverino E, Dambrava P, Cillóniz C, Balasso V, Marcos MA, Esquinas C, Mensa J, Ewig S, Torres A. Nursing home-acquired pneumonia: a 10 year single-centre experience. Thorax. 2010. https://doi.org/10.1136/thx.2009.124776.PubMedCrossRef

29.

Postma D, van Werkhoven C, van Elden LJ, Thijsen SFT, Hoepelman AIM, Kluytmans, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015. https://doi.org/10.1056/nejmoa1406330.CrossRefPubMed

30.

Postma DF, van Werkhoven CH, Oosterheert JJ. Community-acquired pneumonia requiring hospitalization: rational decision making and interpretation of guidelines. Curr Opin Pulm Med. 2017;23(3):204–10. https://doi.org/10.1097/MCP.0000000000000371.CrossRefPubMed

31.

Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462–74.CrossRefPubMed

32.

Micek S, Lloyd A, Ritchie D, Reichley R, Fraser V, Kollef M. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005. https://doi.org/10.1128/AAC.49.4.1306-1311.2005.PubMedPubMedCentralCrossRef

33.

Fraser A, Paul M, Almanasreh N, Tacconelli E, Frank U, Cauda R, et al. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med. 2006. https://doi.org/10.1016/j.amjmed.2006.03.034.PubMedCrossRef

34.

Ciccolini M, Spoorenberg V, Geerlings SE, Prins JM, Grundmann H. Using an index-based approach to assess the population-level appropriateness of empirical antibiotic therapy. J Antimicrob Chemother. 2015. https://doi.org/10.1093/jac/dku336.PubMedCrossRef

35.

Seaton RA, Nathwani D, Burton P, McLaughlin C, MacKenzie AR, Dundas S, et al. Point prevalence survey of antibiotic use in Scottish hospitals utilising the Glasgow Antimicrobial Audit Tool (GAAT). Int J Antimicrob Agents. 2007. https://doi.org/10.1016/j.ijantimicag.2006.10.020.PubMedCrossRef

36.

Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo J, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009. https://doi.org/10.1378/chest.09-0087.CrossRefPubMed

37.

Raveh D, Levy Y, Schlesinger Y, Greenberg A, Rudensky B, Yinnon AM. Longitudinal surveillance of antibiotic use in the hospital. QJM. 2001;94(3):141–52.CrossRefPubMed

38.

James R, Upjohn L, Cotta M, Luu S, Marshall C, Buising K, et al. Measuring antimicrobial prescribing quality in Australian hospitals: development and evaluation of a national antimicrobial prescribing survey tool. J Antimicrob Chemother. 2015. https://doi.org/10.1093/jac/dkv047.CrossRefPubMed

39.

Vlahovic Palcevski V, Francetic I, Palcevski G, Novak S, Abram M, Bergman U. Antimicrobial use at a university hospital: appropriate or misused? A qualitative study. Int J Clin Pharmacol Ther. 2007;45(3):169–74.CrossRefPubMed

40.

Peron E, Hirsch A, Jury L, Jump RLP, Donskey C. Another setting for stewardship: high rate of unnecessary antimicrobial use in a veterans affairs long-term care facility. J Am Geriatr Soc. 2013. https://doi.org/10.1111/jgs.12099.PubMedPubMedCentralCrossRef

41.

van Buul L, Veenhuizen R, Achterberg W, Schellevis F, Essink RT, de Greeff S, et al. Antibiotic prescribing in Dutch nursing homes: how appropriate is it? J Am Med Dir Assoc. 2015. https://doi.org/10.1016/j.jamda.2014.10.003.PubMedCrossRef

42.

Schultz L, Lowe T, Srinivasan A, Neilson D, Pugliese G. Economic impact of redundant antimicrobial therapy in US hospitals. Infect Control Hosp Epidemiol. 2014. https://doi.org/10.1086/678066.PubMedCrossRef

43.

Willemsen I, van der Kooij T, van Benthem B, Wille J, Kluytmans J. Appropriateness of antimicrobial therapy: a multicentre prevalence survey in the Netherlands, 2008–2009. Euro Surveill. 2010.

44.

Hajjar E, Cafiero A, Hanlon J. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007. https://doi.org/10.1016/j.amjopharm.2007.12.002.CrossRefPubMed

45.

Warren JW, Palumbo FB, Fitterman L, Speedie SM. Incidence and characteristics of antibiotic use in aged nursing home patients. J Am Geriatr Soc. 1991;39(10):963–72.CrossRefPubMed

46.

Rotjanapan P, Dosa D, Thomas K. Potentially inappropriate treatment of urinary tract infections in two Rhode Island nursing homes. Arch Intern Med. 2011. https://doi.org/10.1001/archinternmed.2011.13.PubMedCrossRef

47.

Zimmer JG, Bentley DW, Valenti WM, Watson NM. Systemic antibiotic use in nursing homes. A quality assessment. J Am Geriatr Soc. 1986;34(10):703–10.CrossRefPubMed

48.

Pickering TD, Gurwitz JH, Zaleznik D, Noonan JP, Avorn J. The appropriateness of oral fluoroquinolone-prescribing in the long-term care setting. J Am Geriatr Soc. 1994;42(1):28–32.CrossRefPubMed

49.

Loeb M, Simor AE, Landry L, Walter S, McArthur M, Duffy J, et al. Antibiotic use in Ontario facilities that provide chronic care. J Gen Intern Med. 2001;16(6):376–83.CrossRefPubMedPubMedCentral

50.

Vergidis P, Hamer D, Meydani S, Dallal G, Barlam T. Patterns of antimicrobial use for respiratory tract infections in older residents of long-term care facilities. J Am Geriatr Soc. 2011. https://doi.org/10.1111/j.1532-5415.2011.03406.x.PubMedPubMedCentralCrossRef

51.

Spivak E, Cosgrove S, Srinivasan A. Measuring appropriate antimicrobial use: attempts at opening the black box. Clin Infect Dis. 2016. https://doi.org/10.1093/cid/ciw658.PubMedCrossRef

52.

Casaroto E, Marra A, Camargo TZS, de Souza ARA, de Almeida CES, Pedroti E, et al. Agreement on the prescription of antimicrobial drugs. BMC Infect Dis. 2015. https://doi.org/10.1186/s12879-015-0992-y.PubMedPubMedCentralCrossRef

53.

Baclet N, Ficheur G, Alfandari S, Ferret L, Senneville E, Chazard E, et al. Explicit definitions of potentially inappropriate prescriptions of antibiotics in older patients: a compilation derived from a systematic review. Int J Antimicrob Agents. 2017. https://doi.org/10.1016/j.ijantimicag.2017.08.011.PubMedCrossRef

54.

Sogn DD, Evans R, Shepherd GM, Casale TB, Condemi J, Greenberger PA, et al. Results of the National Institute of Allergy and Infectious Diseases Collaborative Clinical Trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med. 1992;152(5):1025–32.CrossRefPubMed

55.

Barnes S, Rock C, Harris A, Cosgrove S, Morgan D, Thom K. The impact of reducing antibiotics on the transmission of multidrug-resistant organisms. Infect Control Hosp Epidemiol. 2017. https://doi.org/10.1017/ice.2017.34.PubMedCrossRef

56.

Barlam T, Cosgrove S, Abbo L, MacDougall C, Schuetz A, Septimus E, et al. Implementing an antibiotic Stewardship Program: guidelines by the infectious diseases society of america and the society for healthcare epidemiology of America. Clin Infect Dis. 2016. https://doi.org/10.1093/cid/ciw118.PubMedCentralCrossRefPubMed

57.

Faulkner C, Cox H, Williamson J. Unique aspects of antimicrobial use in older adults. Clin Infect Dis. 2005. https://doi.org/10.1086/428125.PubMedCrossRef

58.

Tamma P, Avdic E, Li D, Dzintars K, Cosgrove S. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med. 2017. https://doi.org/10.1001/jamainternmed.2017.1938.PubMedCrossRefPubMedCentral

59.

Gurwitz JH, Field TS, Avorn J, McCormick D, Jain S, Eckler MB, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109(2):87–94.CrossRefPubMed

60.

Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001. https://doi.org/10.1067/mem.2001.119456.PubMedCrossRef

61.

van der Linden PD, Sturkenboom MCJM, Herings RMC, Leufkens HMG, Rowlands S, Stricker BHC. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med. 2003. https://doi.org/10.1001/archinte.163.15.1801.CrossRefPubMed

62.

Wise B, Peloquin C, Choi H, Lane N, Zhang Y. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med. 2012. https://doi.org/10.1016/j.amjmed.2012.05.027.PubMedPubMedCentralCrossRef

63.

Fialová D, Topinková E, Gambassi G, Finne Soveri H, Jónsson P, Carpenter I, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA. 2005. https://doi.org/10.1001/jama.293.11.1348.PubMedCrossRef

64.

Ray W, Murray K, Hall K, Arbogast P, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012. https://doi.org/10.1056/NEJMoa1003833.CrossRefPubMedPubMedCentral

65.

Ray W, Murray K, Meredith S, Narasimhulu S, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004. https://doi.org/10.1056/NEJMoa040582.CrossRefPubMed

66.

Mortensen E, Halm E, Pugh M, Copeland L, Metersky M, Fine M, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA. 2014. https://doi.org/10.1001/jama.2014.4304.PubMedCentralCrossRefPubMed

67.

Schembri S, Williamson P, Short P, Akram A, Taylor J, Singanayagam A, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ. 2013. https://doi.org/10.1136/bmj.f1235.PubMedCrossRef

68.

Chou H, Wang J, Chang C, Lai C, Lai M, Chan KA. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and ß-lactam/ß-lactamase inhibitors: a Taiwanese nationwide study. Clin Infect Dis. 2015. https://doi.org/10.1093/cid/ciu914.CrossRefPubMed

69.

Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013. https://doi.org/10.1056/NEJMoa1300799.CrossRefPubMed

70.

Petrosillo N, Cataldo M, Pea F. Treatment options for community-acquired pneumonia in the elderly people. Expert Rev Anti Infect Ther. 2015. https://doi.org/10.1586/14787210.2015.1021783.CrossRefPubMed

71.

Asempa T, Nicolau D. Clostridium difficile infection in the elderly: an update on management. Clin Interv Aging. 2017. https://doi.org/10.2147/CIA.S149089.PubMedPubMedCentralCrossRef

72.

UpToDate. Antimicrobial agents that may induce Clostridium difficile diarrhea and colitis. 2017. https://www.uptodate.com/contents/clostridium-difficile-infection-in-adultstreatment#subscribeMessage. Accessed 23 Dec 2017.

73.

Davey P, Marwick C, Scott C, Charani E, McNeil K, Brown E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017. https://doi.org/10.1002/14651858.CD003543.pub4.PubMedCrossRef

74.

Dellit T, Owens R, McGowan J, Gerding D, Weinstein R, Burke J, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007. https://doi.org/10.1086/510393.PubMedCrossRef

75.

Adam H, Baxter M, Davidson R, Rubinstein E, Fanella S, Karlowsky J, et al. Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals. J Antimicrob Chemother. 2013. https://doi.org/10.1093/jac/dkt024.CrossRefPubMed

76.

Dyar OJ, Huttner B, Schouten J, Pulcini C. What is antimicrobial stewardship? Clin Microbiol Infect. 2017. https://doi.org/10.1016/j.cmi.2017.08.026.CrossRefPubMed

77.

Dean NC, Silver MP, Bateman KA, James B, Hadlock CJ, Hale D. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med. 2001;110(6):451–7.CrossRefPubMed

78.

Dean N, Bateman K, Donnelly S, Silver M, Snow G, Hale D. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest. 2006. https://doi.org/10.1378/chest.130.3.794.PubMedCrossRef

79.

Fowler S, Webber A, Cooper BS, Phimister A, Price K, Carter Y, et al. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series. J Antimicrob Chemother. 2007. https://doi.org/10.1093/jac/dkm014.CrossRefPubMed

80.

McNulty C, Logan M, Donald IP, Ennis D, Taylor D, Baldwin RN, et al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother. 1997;40(5):707–11.CrossRefPubMed

81.

Katz PR, Beam TR, Brand F, Boyce K. Antibiotic use in the nursing home. Physician practice patterns. Arch Intern Med. 1990;150(7):1465–8.CrossRefPubMed

82.

Katz M, Gurses A, Tamma P, Cosgrove S, Miller M, Jump RLP. Implementing antimicrobial stewardship in long-term care settings: an integrative review using a human factors approach. Clin Infect Dis. 2017. https://doi.org/10.1093/cid/cix566.CrossRefPubMed

83.

Crnich C, Jump R, Trautner B, Sloane P, Mody L. Optimizing antibiotic stewardship in nursing homes: a narrative review and recommendations for improvement. Drugs Aging. 2015. https://doi.org/10.1007/s40266-015-0292-7.PubMedPubMedCentralCrossRef

84.

Naughton BJ, Mylotte JM, Ramadan F, Karuza J, Priore RL. Antibiotic use, hospital admissions, and mortality before and after implementing guidelines for nursing home-acquired pneumonia. J Am Geriatr Soc. 2001;49(8):1020–4.CrossRefPubMed

85.

Wenisch J, Equiluz Bruck S, Fudel M, Reiter I, Schmid A, Singer E, et al. Decreasing Clostridium difficile infections by an antimicrobial stewardship program that reduces moxifloxacin use. Antimicrob Agents Chemother. 2014. https://doi.org/10.1128/AAC.03006-14.PubMedPubMedCentralCrossRef

86.

Syrjälä H, Broas M, Suramo I, Ojala A, Lähde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis. 1998;27(2):358–63.CrossRefPubMed

87.

Hagaman J, Rouan G, Shipley R, Panos R. Admission chest radiograph lacks sensitivity in the diagnosis of community-acquired pneumonia. Am J Med Sci. 2009. https://doi.org/10.1097/MAJ.0b013e31818ad805.PubMedCrossRef

88.

Wunderink R, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017. https://doi.org/10.1136/bmj.j2471.PubMedCrossRef

89.

Claessens Y, Debray M, Tubach F, Brun A, Rammaert B, Hausfater P, et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med. 2015. https://doi.org/10.1164/rccm.201501-0017OC.PubMedCrossRef

90.

Llamas Álvarez A, Tenza Lozano E, Latour Pérez J. Accuracy of lung ultrasonography in the diagnosis of pneumonia in adults: systematic review and meta-analysis. Chest. 2017. https://doi.org/10.1016/j.chest.2016.10.039.CrossRefPubMed

91.

Oosterheert J, van Loon A, Schuurman R, Hoepelman AIM, Hak E, Thijsen S, et al. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis. 2005. https://doi.org/10.1086/497134.PubMedCrossRef

92.

Hernes SS, Hagen E, Quarsten H, Bjorvatn B, Bakke PS. No impact of early real-time PCR screening for respiratory viruses on length of stay and use of antibiotics in elderly patients hospitalized with symptoms of a respiratory tract infection in a single center in Norway. Eur J Clin Microbiol Infect Dis. 2014. https://doi.org/10.1007/s10096-013-1963-0.PubMedCrossRef

93.

Tobia C, Aspinall S, Good C, Fine M, Hanlon J. Appropriateness of antibiotic prescribing in veterans with community-acquired pneumonia, sinusitis, or acute exacerbations of chronic bronchitis: a cross-sectional study. Clin Ther. 2008. https://doi.org/10.1016/j.clinthera.2008.06.009.PubMedPubMedCentralCrossRef

Title: Inappropriate Use of Antimicrobials for Lower Respiratory Tract Infections in Elderly Patients: Patient- and Community-Related Implications and Possible Interventions
Authors: Inger van Heijl
Valentijn A. Schweitzer
Lufang Zhang
Paul D. van der Linden
Cornelis H. van Werkhoven
Douwe F. Postma
Publication date: 01-05-2018
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 5/2018
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-018-0541-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2018

Medications and Prescribing Patterns as Factors Associated with Hospitalizations from Long-Term Care Facilities: A Systematic Review

Abatacept for Treatment of Rheumatoid Arthritis: Special Focus on the Elderly

An Analysis of the Inclusion of Medications Considered Potentially Inappropriate in Older Adults in Chemotherapy Templates for Hematologic Malignancies: One Recommendation for All?

Characteristics of New-Onset and Chronic Sleep Medication Users Among Older Adults: A Retrospective Study of a US Medigap Plan Population using Propensity Score Matching

Clinical Pharmacy Services on Geriatric Care Wards: Catch 22 of Implementation and Research

A Glimpse into Uveitis in the Aging Eye: Pathophysiology, Clinical Presentation and Treatment Considerations

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials